Key facts
- The FLOW trial presented findings at the 63rd ERA Congress.
- Semaglutide significantly improved health-related quality of life.
- The study focused on adults with type 2 diabetes and chronic kidney disease.
New findings from the landmark FLOW trial were presented at the 63rd ERA Congress in Glasgow, Scotland. The study demonstrated that once-weekly semaglutide significantly improved health-related quality of life in adults diagnosed with type 2 diabetes (T2D) and chronic kidney disease (CKD). The results highlight the drug's potential benefits beyond glycemic control and kidney function preservation.